Literature DB >> 23453200

Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.

Wei Gao1, Bai Xiang1, Ting-Ting Meng1, Feng Liu2, Xian-Rong Qi3.   

Abstract

Chemotherapeutic agents often cause severe side effects because they produce a similar cytotoxicity in both cancerous and healthy cells. In this study, a rational strategy was implemented to take advantage of a combination of both tumor microenvironment-sensitive polypeptides (TMSP) and folate to create a more selective and efficient drug delivery system to target cancer cells. TMSP and folate were conjugated to the distal ends of DSPE-PEG2000-maleimide and DSPE-PEG5000-amine to create DSPE-PEG2000-TMSP and DSPE-PEG5000-folate, respectively, which were incorporated onto the surface of a docetaxel-loaded nanostructured lipid carrier (F/TMSP-DTX-NLC). TMSP are comprised of polycationic cell-penetrating peptides (CPP) and polyanionic inhibitory peptides, which are coupled via a proteinase-sensitive cleavable linker. The linker can be cleaved in the presence of matrix metalloprotease-2 and -9 (MMP-2/9). TMSP provides the ability to enhance specific cancer cellular uptake after selectively unmasking polyanionic inhibitory peptides in MMP-2/9 protease-oversecretion tumor tissue, whereas in circulation, the penetration is shielded. The folate moiety binds selectively to folate receptor-positive tumors. The cleaved dual-modified nanocarriers are then taken up by the tumor cells via both receptor-mediated endocytosis and CPP penetrating action to overcome the higher interstitial pressure in the tumor. The nanocarrier system demonstrated a small size, high encapsulation efficiency (>95%), sustained release and targeted delivery. The strong cellular uptake and cytotoxic activity of dual-modified F/TMSP-DTX-NLC in KB, HT-1080, MCF-7 and A549 cells verified the correlation with folate receptor expression and MMP-2/9 secretion. The remarkable penetration into KB and HT-1080 multicellular tumor spheroids confirmed that the temporary mask of the polyanionic inhibitory peptide in TMSP does not disturb the penetration ability of CPP in the tumor microenvironment with abundant proteases. Furthermore, the active targeting and triggered activation exhibited higher antitumor efficacy and lower systemic toxicity with the KB tumor model in nude mice compared to the nonmodified DTX-NLC and Taxotere(®). These results suggested that the application of combined TMSP and folate modifications may be an approach in the selectively targeted delivery of anticancer drugs with low systemic toxicity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453200     DOI: 10.1016/j.biomaterials.2013.02.014

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  32 in total

Review 1.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 2.  Nanotechnology: Future of Oncotherapy.

Authors:  Kshipra M Gharpure; Sherry Y Wu; Chun Li; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-07-15       Impact factor: 12.531

3.  Sustained release of methotrexate through liquid-crystalline folate nanoparticles.

Authors:  Rahul Misra; Sanat Mohanty
Journal:  J Mater Sci Mater Med       Date:  2014-06-22       Impact factor: 3.896

Review 4.  Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.

Authors:  Izabela Rusiecka; Iwona Gągało; Ivan Kocić
Journal:  Tissue Barriers       Date:  2021-08-17

5.  Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy.

Authors:  Yaqiao Li; Lingxiao Li; Qianhui Jin; Tian Liu; Jin Sun; Yongjun Wang; Zhijun Yang; Zhonggui He; Bingjun Sun
Journal:  Asian J Pharm Sci       Date:  2022-02-27       Impact factor: 9.273

6.  Targeting tamoxifen to breast cancer xenograft tumours: preclinical efficacy of folate-attached nanoparticles based on alginate-cysteine/disulphide-bond-reduced albumin.

Authors:  A Martínez; E Muñiz; C Teijón; I Iglesias; J M Teijón; M D Blanco
Journal:  Pharm Res       Date:  2013-11-12       Impact factor: 4.200

Review 7.  Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics.

Authors:  Elly De Vlieghere; Laurine Verset; Pieter Demetter; Marc Bracke; Olivier De Wever
Journal:  Virchows Arch       Date:  2015-08-11       Impact factor: 4.064

Review 8.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 9.  How nanotechnology can enhance docetaxel therapy.

Authors:  Li Zhang; Na Zhang
Journal:  Int J Nanomedicine       Date:  2013-08-07

10.  Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA.

Authors:  Daxiang Cui; Chunlei Zhang; Bing Liu; Yi Shu; Tong Du; Dan Shu; Kan Wang; Fangping Dai; Yanlei Liu; Chao Li; Fei Pan; Yuming Yang; Jian Ni; Hui Li; Beate Brand-Saberi; Peixuan Guo
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.